

Supplemental Table 1. Series Reported in Table 1. For each reference, number of patients with mutation/number tested (% with mutation) is indicated.

Juvenile Myelomonocytic Leukemia (JMML):

Reference	NRAS	KRAS	NF1
(Park et al., 2012)	2/22 (9%)	1/22 (5%)	--
(Pérez et al., 2010)	11/68 (16%)	12/68 (18%)	3/68 (4%)
(Yoshida et al., 2009)	11/71 (15%)	2/71 (3%)	--
(Chen et al., 2006)	4/15 (27%)	1/15 (7%)	--
(Flotho et al., 1999)	5/36 (14%)	1/36 (3%)	--
(Miyachi et al., 1994)	6/20 (30%)	--	--
(Kalra et al., 1994)	3/11 (27%)	2/11 (18%)	--
(Padua et al., 1988)	3/20 (15%)	1/20 (5%)	3/20 (15%)
TOTAL	45/263 (17%)	20/243 (8%)	6/88 (7%)

Chronic Myelomonocytic Leukemia (CMML):

Reference	NRAS	KRAS	NF1
(Jankowska et al., 2011)	1/52 (2%)	4/52 (8%)	--
(Ricci et al., 2010)	6/18 (33%)	1/18 (6%)	--
(Kohlmann et al., 2010)	18/81 (22%)	10/81 (12%)	--
(Tyner et al., 2009)	3/26 (12%)	4/26 (15%)	--
(Gelsi-Boyer et al., 2008)	2/24 (8%)	2/24 (8%)	--
(Hirsch-Ginsberg et al., 1990)	13/30 (43%)	4/30 (13%)	--
TOTAL	43/231 (19%)	25/231 (11%)	--

Acute Myelogenous Leukemia (AML):

Reference	NRAS	KRAS	NF1
(Berman et al., 2011)	86/825 (10%)	2/183 (1%)	--
(Parkin et al., 2010)	--	--	7/95 (7%)
(Bacher et al., 2006)	257/2502 (10%)	--	--
(Bowen et al., 2005)	126/1106 (11%)	39/739 (5%)	--
(Lee et al., 1995)	10/48 (21%)	--	0/48 (0%)
(Vogelstein et al., 1990)	24/99 (24%)	13/99 (13%)	--
(Bartram et al., 1989)	13/57 (23%)	2/57 (4%)	--
(Senn et al., 1988)	5/18 (28%)	--	--
(Farr et al., 1988)	14/52 (27%)	--	--

(Bos et al., 1987)	5/37 (14%)	2/37 (5%)	--
(Janssen et al., 1987)	4/9 (44%)	--	--
TOTAL	544/4753 (11%)	58/1115 (5%)	7/143 (5%)

Myelodysplastic Syndrome (MDS):

Reference	NRAS	KRAS	NF1
(Kolquist et al., 2011)	--	--	3/35 (9%)
(Bejar et al., 2011)	16/439 (4%)	4/439 (1%)	--
(Dicker et al., 2010)	6/163 (4%)	--	--
(Bacher et al., 2007)	17/272 (6%)	--	--
(Misawa et al., 1997)	6/70 (9%)	--	0/70 (0%)
(Janssen et al., 1987)	0/13 (0%)	0/13 (0%)	--
(Hirai et al., 1987)	3/8 (4%)	0/8 (0%)	--
TOTAL	48/965 (5%)	4/460 (1%)	3/105 (3%)

Acute Lymphocytic Leukemia (ALL):

Reference	NRAS	KRAS	NF1
(Zhang et al., 2012)	15/106 (14%)	2/106 (2%)	9/106 (8%)
(Balgobind et al., 2008)	-	-	3/103 (3%) (T-ALL only)
(Perentesis et al., 2004)	81/870 (9%)	41/870 (5%)	-
(Neri et al., 1988)	6/33 (18%)	0/33 (0%)	-
(Senn et al., 1988)	0/14 (0%)	-	-
(Rodenhuis et al., 1986)	2/19 (11%)	-	-
TOTAL	104/1042 (10%)	43/1009 (4%)	12/209 (6%)

Multiple Myeloma (MM):

Reference	NRAS	KRAS	NF1
(Chng et al., 2008)	74/439 (17%)	28/439 (6%)	-
(Liu et al., 1996)	61/346 (18%)	23/246 (7%)	-
(Neri et al., 1989)	17/56 (30%)	5/56 (9%)	-
TOTAL	152/841 (18%)	56/741 (8%)	-

Supplemental References:

Bacher, U., Haferlach, T., Kern, W., Haferlach, C., and Schnittger, S. (2007). A

comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. *Haematologica* 92, 744–752.

Bacher, U., Haferlach, T., Schoch, C., Kern, W., and Schnittger, S. (2006). Implications of NRAS mutations in AML: a study of 2502 patients. *Blood* 107, 3847–3853.

Balgobind, B.V., Van Vlierberghe, P., van den Ouweland, A.M.W., Beverloo, H.B., Terlouw-Kromosoeto, J.N.R., van Wering, E.R., Reinhardt, D., Horstmann, M., Kaspers, G.J.L., Pieters, R., et al. (2008). Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis. *Blood* 111, 4322–4328.

Bartram, C.R., Ludwig, W.D., Hiddemann, W., Lyons, J., Buschle, M., Ritter, J., Harbott, J., Fröhlich, A., and Janssen, J.W. (1989). Acute myeloid leukemia: analysis of ras gene mutations and clonality defined by polymorphic X-linked loci. *Leukemia* 3, 247–256.

Bejar, R., Stevenson, K., Abdel-Wahab, O., Galili, N., Nilsson, B., Garcia-Manero, G., Kantarjian, H., Raza, A., Levine, R.L., Neuberg, D., et al. (2011). Clinical effect of point mutations in myelodysplastic syndromes. *N Engl J Med* 364, 2496–2506.

Berman, J.N., Gerbing, R.B., Alonzo, T.A., Ho, P.A., Miller, K., Hurwitz, C., Heerema, N.A., Hirsch, B., Raimondi, S.C., Lange, B., et al. (2011). Prevalence and clinical implications of NRAS mutations in childhood AML: a report from the Children's Oncology Group. *Leukemia* 25, 1039–1042.

Bos, J.L., Verlaan-de Vries, M., van der Eb, A.J., Janssen, J.W., Delwel, R., Löwenberg, B., and Colly, L.P. (1987). Mutations in N-ras predominate in acute myeloid leukemia. *Blood* 69, 1237–1241.

Bowen, D.T., Frew, M.E., Hills, R., Gale, R.E., Wheatley, K., Groves, M.J., Langabeer, S.E., Kottaridis, P.D., Moorman, A.V., Burnett, A.K., et al. (2005). RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years. *Blood* 106, 2113–2119.

Chen, Y., Takita, J., Hiwatari, M., Igarashi, T., Hanada, R., Kikuchi, A., Hongo, T., Taki, T., Ogasawara, M., Shimada, A., et al. (2006). Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies. *Genes Chromosomes Cancer* 45, 583–591.

Chng, W.J., Gonzalez-Paz, N., Price-Troska, T., Jacobus, S., Rajkumar, S.V., Oken, M.M., Kyle, R.A., Henderson, K.J., Van Wier, S., Greipp, P., et al. (2008). Clinical and biological significance of RAS mutations in multiple myeloma. *Leukemia* 22, 2280–2284.

Dicker, F., Haferlach, C., Sundermann, J., Wendland, N., Weiss, T., Kern, W., Haferlach, T., and Schnittger, S. (2010). Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML. *Leukemia* 24, 1528–1532.

Farr, C.J., Saiki, R.K., Erlich, H.A., McCormick, F., and Marshall, C.J. (1988). Analysis of RAS gene mutations in acute myeloid leukemia by polymerase chain reaction and oligonucleotide probes. *Proc Natl Acad Sci USA* 85, 1629–1633.

Flotho, C., Valcamonica, S., Mach-Pascual, S., Schmahl, G., Corral, L., Ritterbach, J., Hasle, H., Aricò, M., Biondi, A., and Niemeyer, C.M. (1999). RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML). *Leukemia* 13, 32–37.

Gelsi-Boyer, V., Trouplin, V., Adélaïde, J., Aceto, N., Remy, V., Pinson, S., Houdayer, C., Arnoulet, C., Sainty, D., Bentires-Alj, M., et al. (2008). Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes. *BMC Cancer* 8, 299.

Hirai, H., Kobayashi, Y., Mano, H., Hagiwara, K., Maru, Y., Omine, M., Mizoguchi, H., Nishida, J., and Takaku, F. (1987). A point mutation at codon 13 of the N-ras oncogene in myelodysplastic syndrome. *Nature* 327, 430–432.

Hirsch-Ginsberg, C., LeMaistre, A.C., Kantarjian, H., Talpaz, M., Cork, A., Freireich, E.J., Trujillo, J.M., Lee, M.S., and Stass, S.A. (1990). RAS mutations are rare events in Philadelphia chromosome-negative/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia. *Blood* 76, 1214–1219.

Jankowska, A.M., Makishima, H., Tiu, R.V., Szpurka, H., Huang, Y., Traina, F., Visconte, V., Sugimoto, Y., Prince, C., O'Keefe, C., et al. (2011). Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. *Blood* 118, 3932–3941.

Janssen, J.W., Steenvoorden, A.C., Lyons, J., Anger, B., Böhlke, J.U., Bos, J.L., Seliger, H., and Bartram, C.R. (1987). RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes. *Proc Natl Acad Sci USA* 84, 9228–9232.

Kalra, R., Paderanga, D.C., Olson, K., and Shannon, K.M. (1994). Genetic analysis is consistent with the hypothesis that NF1 limits myeloid cell growth through p21ras. *Blood* 84, 3435–3439.

Kohlmann, A., Grossmann, V., Klein, H.-U., Schindela, S., Weiss, T., Kazak, B., Dicker, F., Schnittger, S., Dugas, M., Kern, W., et al. (2010). Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in

TET2, CBL, RAS, and RUNX1. *Journal of Clinical Oncology* 28, 3858–3865.

Kolquist, K.A., Schultz, R.A., Furrow, A., Brown, T.C., Han, J.-Y., Campbell, L.J., Wall, M., Slovak, M.L., Shaffer, L.G., and Ballif, B.C. (2011). Microarray-based comparative genomic hybridization of cancer targets reveals novel, recurrent genetic aberrations in the myelodysplastic syndromes. *Cancer Genet* 204, 603–628.

Lee, Y.Y., Kim, W.S., Bang, Y.J., Jung, C.W., Park, S., Yoon, W.J., Cho, K.S., Kim, I.S., Jung, T.J., and Choi, I.Y. (1995). Analysis of mutations of neurofibromatosis type 1 gene and N-ras gene in acute myelogenous leukemia. *Stem Cells* 13, 556–563.

Liu, P., Leong, T., Quam, L., Billadeau, D., Kay, N.E., Greipp, P., Kyle, R.A., Oken, M.M., and Van Ness, B. (1996). Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial. *Blood* 88, 2699–2706.

Misawa, S., Horiike, S., Kaneko, H., and Kashima, K. (1997). Genetic aberrations in the development and subsequent progression of myelodysplastic syndrome. *Leukemia* 11 Suppl 3, 533–535.

Miyauchi, J., Asada, M., Sasaki, M., Tsunematsu, Y., Kojima, S., and Mizutani, S. (1994). Mutations of the N-ras gene in juvenile chronic myelogenous leukemia. *Blood* 83, 2248–2254.

Neri, A., Knowles, D.M., Greco, A., McCormick, F., and Dalla-Favera, R. (1988). Analysis of RAS oncogene mutations in human lymphoid malignancies. *Proc Natl Acad Sci USA* 85, 9268–9272.

Neri, A., Murphy, J.P., Cro, L., Ferrero, D., Tarella, C., Baldini, L., and Dalla-Favera, R. (1989). Ras oncogene mutation in multiple myeloma. *J. Exp. Med.* 170, 1715–1725.

Padua, R.A., Carter, G., Hughes, D., Gow, J., Farr, C., Oscier, D., McCormick, F., and Jacobs, A. (1988). RAS mutations in myelodysplasia detected by amplification, oligonucleotide hybridization, and transformation. *Leukemia* 2, 503–510.

Park, H.-D., Lee, S.H., Sung, K.W., Koo, H.H., Jung, N.G., Cho, B., Kim, H.K., Park, I.-A., Lee, K.-O., Ki, C.-S., et al. (2012). Gene mutations in the Ras pathway and the prognostic implication in Korean patients with juvenile myelomonocytic leukemia. *Ann Hematol* 91, 511–517.

Parkin, B., Ouillette, P., Wang, Y., Liu, Y., Wright, W., Roulston, D., Purkayastha, A., Dressel, A., Karp, J., Bockenstedt, P., et al. (2010). NF1 inactivation in adult acute myelogenous leukemia. *Clin Cancer Res* 16, 4135–4147.

Perentesis, J.P., Bhatia, S., Boyle, E., Shao, Y., Shu, X.O., Steinbuch, M., Sather, H.N., Gaynon, P., Kiffmeyer, W., Envall-Fox, J., et al. (2004). RAS oncogene mutations and outcome of therapy for childhood acute lymphoblastic leukemia. *Leukemia* 18, 685–692.

Pérez, B., Kosmider, O., Cassinat, B., Renneville, A., Lachenaud, J., Kaltenbach, S., Bertrand, Y., Baruchel, A., Chomienne, C., Fontenay, M., et al. (2010). Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia. *Br J Haematol* 151, 460–468.

Ricci, C., Fermo, E., Corti, S., Molteni, M., Faricciotti, A., Cortelezzi, A., Lambertenghi Deliliers, G., Beran, M., and Onida, F. (2010). RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant. *Clin Cancer Res* 16, 2246–2256.

Rodenhuis, S., Bos, J.L., Slater, R.M., Behrendt, H., van 't Veer, M., and Smets, L.A. (1986). Absence of oncogene amplifications and occasional activation of N-ras in lymphoblastic leukemia of childhood. *Blood* 67, 1698–1704.

Senn, H.P., Trân-Thang, C., Wodnar-Filipowicz, A., Jiricny, J., Fopp, M., Gratwohl, A., Signer, E., Weber, W., and Moroni, C. (1988). Mutation analysis of the N-ras proto-oncogene in active and remission phase of human acute leukemias. *Int. J. Cancer* 41, 59–64.

Tyner, J.W., Erickson, H., Deininger, M.W.N., Willis, S.G., Eide, C.A., Levine, R.L., Heinrich, M.C., Gattermann, N., Gilliland, D.G., Druker, B.J., et al. (2009). High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. *Blood* 113, 1749–1755.

Vogelstein, B., Civin, C.I., Preisinger, A.C., Krischer, J.P., Steuber, P., Ravindranath, Y., Weinstein, H., Elfferich, P., and Bos, J. (1990). RAS gene mutations in childhood acute myeloid leukemia: a Pediatric Oncology Group study. *Genes Chromosomes Cancer* 2, 159–162.

Yoshida, N., Yagasaki, H., Xu, Y., Matsuda, K., Yoshimi, A., Takahashi, Y., Hama, A., Nishio, N., Muramatsu, H., Watanabe, N., et al. (2009). Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia. *Pediatr. Res.* 65, 334–340.

Zhang, J., Ding, L., Holmfeldt, L., Wu, G., Heatley, S.L., Payne-Turner, D., Easton, J., Chen, X., Wang, J., Rusch, M., et al. (2012). The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. *Nature* 481, 157–163.